# NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

> **NCT05005845** · PHASE2 · COMPLETED · sponsor: **NFlection Therapeutics, Inc.** · enrollment: 199 (actual)

## Conditions studied

- Cutaneous Neurofibroma
- Neurofibromatosis 1

## Interventions

- **DRUG:** NFX-179 gel
- **DRUG:** Vehicle gel

## Key facts

- **NCT ID:** NCT05005845
- **Lead sponsor:** NFlection Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-29
- **Primary completion:** 2023-10-02
- **Final completion:** 2023-10-02
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05005845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05005845, "NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05005845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*